There is no cure for dementia, but several treatments can slow cognitive decline, ease symptoms, and improve quality of life. The options range from FDA-approved medications that target brain chemistry to newer antibody therapies that clear toxic proteins, alongside non-drug approaches like structured cognitive therapy. What’s available to you depends on the type of dementia, how far it has progressed, and which symptoms are most disruptive.
Medications That Slow Cognitive Decline
The longest-established drug treatments for Alzheimer’s disease, the most common form of dementia, work by boosting chemical signaling between brain cells. Three medications in a class called cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are prescribed for mild to moderate stages. They prevent the breakdown of a chemical messenger involved in memory and learning, which helps brain cells communicate more effectively for a period of time. A fourth drug, memantine, is used in moderate to severe stages and works through a different mechanism, protecting brain cells from overstimulation by a different signaling chemical.
These medications don’t stop the underlying disease from progressing. They do, however, provide a meaningful window of benefit. In one clinical trial, withdrawing donepezil from patients with moderate to severe Alzheimer’s increased the risk of nursing home placement within 12 months. That finding captures what these drugs offer in practical terms: not a reversal, but a period of better functioning that can keep someone more independent for longer.
Newer Antibody Therapies for Early Alzheimer’s
A newer class of treatments goes after one of the physical hallmarks of Alzheimer’s: sticky protein clumps called amyloid plaques that build up in the brain. Two antibody therapies, lecanemab and donanemab, are now FDA-approved. Donanemab (brand name Kisunla) received approval in July 2024. Both are given by infusion and work by binding to amyloid proteins, helping the body clear them from brain tissue.
The benefits are real but modest. In clinical trials, lecanemab slowed the rate of cognitive and functional decline by roughly 25% over 18 months compared to a placebo. That translates to about four to five extra months before reaching the same level of decline. Donanemab performed somewhat better in its primary study population, slowing decline by approximately 35% over the same period.
These therapies are only approved for people in the earliest stages: those with mild cognitive impairment or mild dementia who have confirmed amyloid buildup in the brain. They carry a notable risk of brain swelling or small brain bleeds, a side effect called amyloid-related imaging abnormalities (ARIA). Before starting treatment, patients are tested for a genetic marker called ApoE ε4, which increases the risk of this complication. Regular brain scans are needed throughout treatment to monitor for it.
Treating Agitation and Behavioral Symptoms
Dementia often brings symptoms beyond memory loss. Agitation, aggression, anxiety, hallucinations, and sleep disruption are common, particularly in later stages, and they can be more distressing for both the person with dementia and their caregivers than the cognitive decline itself.
For agitation specifically, brexpiprazole (brand name Rexulti) became the first FDA-approved treatment for agitation associated with Alzheimer’s dementia. It’s taken as a daily tablet, starting at a low dose and gradually increasing over about two weeks. Common side effects include headache, dizziness, urinary tract infections, and sleep disturbances. The drug carries a boxed warning, the most serious safety label, noting that antipsychotic medications increase the risk of death in elderly patients with dementia-related psychosis. This reflects a broader tension in dementia care: the medications available for severe behavioral symptoms carry significant risks, so they’re typically reserved for situations where non-drug approaches haven’t been enough.
Cognitive Stimulation Therapy
Not all effective treatments come in a bottle. Cognitive Stimulation Therapy (CST) is a structured group program that has shown benefits comparable to standard dementia medication for people with mild to moderate dementia. It involves 14 sessions, each lasting 45 minutes, held twice a week over seven weeks. Each session covers a different theme and includes warm-up activities, group discussion, and orientation exercises covering things like the date, time, and location.
Trials have found that CST improves memory and thinking skills, and participants report better quality of life. Caregivers have noticed improvements in language ability and willingness to engage in conversation. Importantly, CST provides benefits on top of whatever medication someone is already taking, not just as a substitute. A maintenance program of 24 additional weekly sessions has been shown to sustain quality-of-life improvements at three and six months. The combination of medication plus ongoing CST has been found more cost-effective than medication alone in formal economic analyses.
Diet, Exercise, and Risk Reduction
Lifestyle factors play a larger role than many people expect. The MIND diet, a hybrid of Mediterranean and heart-healthy eating patterns that emphasizes leafy greens, berries, nuts, whole grains, fish, and olive oil, has shown consistent associations with better cognitive outcomes. In a study of more than 3,400 older adults, following the MIND diet was linked to 32% lower odds of cognitive decline, even without regular exercise. Those who combined the diet with high-intensity physical activity scored even better on cognitive tests, though the exercise alone, without the dietary pattern, did not predict improved outcomes.
This doesn’t mean exercise is unimportant. Physical activity supports cardiovascular health, which directly affects blood flow to the brain and is central to vascular dementia, the second most common type. But the data suggest that what you eat may matter at least as much as how much you move when it comes to protecting cognitive function. Neither diet nor exercise can reverse dementia that has already developed, but both can meaningfully influence the speed of decline and overall well-being.
Why a Cure Remains Elusive
The reason dementia has no cure comes down to its complexity. What gets diagnosed as a single condition often involves multiple overlapping disease processes. Mixed dementia, where Alzheimer’s pathology coexists with vascular damage or other brain changes, is now recognized as the most common form. Each person’s combination of contributing factors is different, which is why the National Institute on Aging has emphasized that risk reduction strategies are not “one size fits all.”
The current generation of treatments targets specific pieces of the puzzle: amyloid plaques, chemical signaling, inflammation, behavioral circuits. None addresses the full picture. Researchers are investigating anti-inflammatory agents and other novel approaches in advanced clinical trials, but the fundamental challenge remains that by the time symptoms appear, significant and irreversible brain changes have already occurred. The most promising direction in dementia research is not just better treatment but earlier detection, catching the disease in its biological stages before it manifests as noticeable memory loss.